RSNA: Percutaneous Image-Guided Biopsy is 'Safe and Highly Diagnostic' for Renal Masses

Share this content:

(ChemotherapyAdvisor) – Image-guided percutaneous core biopsy of renal masses (RMB) allows highly accurate differentiation of benign and malignant renal masses with few complications, according to results from a retrospective study presented at the Radiological Society of North America (RSNA)'s 2012 Scientific Assembly and Annual Meeting in Chicago, IL.

“Percutaneous image-guided RMB is safe and highly diagnostic when combined with IHC studies, and supports a greater role of RMB with imaging to sub-classify renal masses,” reported senior coauthor Steven Raman, MD, of the Ronald Reagan UCLA Medical Center in Los Angeles, CA, and coauthors.

The authors analyzed medical records for 159 patients (71.7% male; mean age, 69 years) who underwent RMB during 2002 to 2012.

Image-guided RMB had a malignancy-detection sensitivity of 100% and specificity of 100%, the coauthors reported.

Patients experienced relatively low rates of complications, most of which were minor, the authors noted.

“There were a total of 12 (7.4%) complications, 11 minor (6.8%) and 1 major,” they reported. “Of the minor complications, 7 (4.3%) were post-procedural minor hematomas that resolved conservatively; 1 (0.6%) post-procedural vasovagal reaction; 1 (0.6%) cases of hematuria; and 2 (1.2%) cases of small free fluid in the pelvis.”

The technique will allow “more targeted management of renal masses,” the coauthors concluded.

Abstract

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs